| Ytd | 5.61% | |
| 1y | 36.93% |
| Open | 5.04 | Prev Close | 5.07 | Low | 4.99 | High | 5.11 | Mkt Cap | 1.01B |
| Vol | 3.56M | Avg Vol | 2.73M | EPS | 0.79 | P/E | 6.43 | Forward P/E | -30.74 |
| Beta | 0.60 | Short Ratio | 13.20 | Inst. Own | 72.25% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-16 | 50-d Avg | 4.69 | 200-d Avg | 4.48 | 1yr Est | 5.51 |
Bank of America Corp DE lowered its stake in Arbutus Biopharma Corporation (NASDAQ: ABUS) by 8.1% du
WARMINSTER, Pa., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Ar
Arbutus Biopharma (ABUS) stock rises after announcing a $230M stock buyback via a modified Dutch auc
Arbutus Biopharma Corporation (NASDAQ:ABUS) ("Arbutus" or the "Company"), a clinical
WARMINSTER, Pa., Aug. 21, 2026 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Ar
Arbutus Biopharma (NASDAQ: ABUS - Get Free Report) and YD Bio (NASDAQ: YDES - Get Free Report) are b
Arbutus Biopharma (NASDAQ:ABUS) reported quarterly losses of $(0.03) per share which missed the anal
Maintained strong financial position with cash, cash equivalents and marketable securities of $92.6M
CHICAGO--(BUSINESS WIRE)--GE HealthCare today announced the launch of Invenia™ ABUS (Automated Breas
Arbutus and its exclusive licensee, Genevant, filed three international lawsuits seeking to enforce
Arbutus and its exclusive licensee, Genevant, filed three international lawsuits seeking to enforce
Arbutus Biopharma is now much better capitalized after Moderna validated the value of its LNP patent
Arbutus Biopharma (NASDAQ:ABUS) reported quarterly earnings of $0.87 per share which beat the analys
Q1 total revenue of $179.1M includes estimated license revenue from Genevant related to litigation s
Moderna stock rises after EU approval of flu-COVID combo vaccine mCOMBRIAX, backed by Phase 3 data s
U.S. stock futures up, QuidelOrtho shares down in pre-market trading. Allbirds, MIND, Arbutus Biopha
J B Hunt Transport Services Inc (JBHT) stock rose in pre-market trading after beating earnings estim
Arbutus Biopharma Corporation (Nasdaq: ABUS) ("Arbutus" or the "Company"), a clinica
Fast Track designation has the potential to facilitate development and accelerate FDA review of imdu
Arbutus Biopharma (NASDAQ:ABUS) reported quarterly losses of $(0.01) per share which beat the analys
Strong financial position with cash, cash equivalents and marketable securities of $91.5M as of Dece
Moderna shares jump after a $950 million settlement over COVID-19 vaccine patents, easing investor c
Box Inc (BOX) shares jump 6.2% in pre-market trading after beating earnings expectations with $305
The company will appeal to a federal circuit court to argue that it has limited liability due to its
Genevant Sciences, a leading nucleic acid delivery company with world-class platforms and a robust l
Moderna to pay $950 million with no future royalties to resolve all global litigation; corresponding
Moderna to pay Genevant and Arbutus $950 million upfront and an additional $1.3 billion contingent u
Moderna to pay Genevant and Arbutus $950 million upfront and an additional $1.3 billion contingent u
Arbutus Biotech faces a pivotal March jury trial against Moderna over LNP patent infringement, creat
Arbutus (ABUS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the com
Chardan Capital analyst Keay Nakae maintains Arbutus Biopharma (NASDAQ:ABUS) with a Buy and maint
Arbutus Biopharma (NASDAQ:ABUS) reported quarterly losses of $(0.04) per share which missed the anal
Strong financial position with cash, cash equivalents and marketable securities of $93.7M Modern
Multiple abstracts accepted featuring imdusiran clinical data – highlighting progress toward a poten
Here is how Arbutus Biopharma (ABUS) and Boston Scientific (BSX) have performed compared to their se
Chardan Capital analyst Keay Nakae maintains Arbutus Biopharma (NASDAQ:ABUS) with a Buy and maint
Companies Reporting Before The Bell • Frontline (NYSE:FRO) is expected to report quarterly earnings
Companies Reporting Before The Bell • CorEnergy Infr Tr (NYSE:CORR) is estimated to report earnings
Companies Reporting Before The Bell • Cedar Fair (NYSE:FUN) is likely to report quarterly earnings
Companies Reporting Before The Bell • Cedar Fair (NYSE:FUN) is estimated to report quarterly loss a
Companies Reporting Before The Bell • argenx (NASDAQ:ARGX) is expected to report quarterly loss at
Companies Reporting Before The Bell • GCM Grosvenor (NASDAQ:GCMG) is likely to report quarterly ear
Here's a roundup of top developments in the biotech space over the last 24 hours:
Companies Reporting Before The Bell • Toyota Motor (NYSE:TM) is projected to report earnings for
Companies Reporting Before The Bell • Mirum Pharmaceuticals (NASDAQ:MIRM) is expected to report
During Thursday, 849 stocks hit new 52-week lows.
Companies Reporting Before The Bell • Travelzoo (NASDAQ:TZOO) is expected to report quarterly ea